RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $9.56 Consensus PT from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has earned a consensus recommendation of “Hold” from the thirteen ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $9.56.

Several equities analysts recently commented on the company. Stifel Nicolaus reiterated a “hold” rating and set a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. HC Wainwright raised shares of RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a research note on Thursday, December 26th. Wells Fargo & Company decreased their target price on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. JPMorgan Chase & Co. lowered shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Finally, Piper Sandler lowered shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $8.00 to $2.00 in a report on Monday, November 11th.

Hedge Funds Weigh In On RAPT Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in RAPT. Readystate Asset Management LP acquired a new stake in RAPT Therapeutics in the 3rd quarter valued at $36,000. Bank of New York Mellon Corp grew its stake in shares of RAPT Therapeutics by 24.0% in the second quarter. Bank of New York Mellon Corp now owns 114,590 shares of the company’s stock valued at $349,000 after buying an additional 22,175 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after buying an additional 25,130 shares during the period. Barclays PLC boosted its holdings in RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after acquiring an additional 29,195 shares during the period. Finally, Los Angeles Capital Management LLC boosted its holdings in RAPT Therapeutics by 66.2% in the 2nd quarter. Los Angeles Capital Management LLC now owns 84,586 shares of the company’s stock worth $258,000 after acquiring an additional 33,692 shares during the period. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Price Performance

RAPT Therapeutics stock opened at $1.72 on Friday. The stock has a market capitalization of $60.13 million, a P/E ratio of -0.62 and a beta of 0.07. RAPT Therapeutics has a 12-month low of $0.79 and a 12-month high of $27.35. The firm’s 50-day moving average is $1.48 and its two-hundred day moving average is $2.09.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.09. As a group, analysts forecast that RAPT Therapeutics will post -2.86 EPS for the current year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.